PreludeDx
PreludeDx
Claim
PreludeDx was founded to deliver actionable tools to manage early stage breast cancer. PreludeDx's first diagnostic test, DCISionRT is the result of over a decade of research and development focused on DCIS. PreludeDx began developing its DCIS test in 2009 after licensing technology from University of California, San Francisco.PreludeDx was founded to deliver actionable tools to manage early stage breast cancer. PreludeDx's f Show More
Alpha Score
$ 48.10 M
Alpha Score
76.2
Predictions
Overview
Team
Financials- Partnerships
Relationships
Locations
Competitors
Comparison
News
Product
Regulatory
Clinical
Patent
Publications
Notes
0and0